Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25108883 | 1.00 | HRH3 (0.44) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25109097 | 0.91 | KDM4E (0.46) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL24514521 | 0.90 | HRH3 (0.43) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL24514528 | 0.90 | HRH3 (0.43) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL22794084 | 0.89 | KDM4E (0.44) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25110045 | 0.89 | KDM4E (0.44) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25468414 | 0.88 | HRH3 (0.43) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25468417 | 0.88 | HRH3 (0.43) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL22794089 | 0.88 | HRH3 (0.43) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL22794231 | 0.87 | HRH3 (0.42) | HRH3KDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH3 1490/4885KDM4E 624/4885ALDH1A1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.